IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
18.82
+0.19 (1.02%)
Apr 23, 2025, 4:00 PM EDT - Market closed
IDEAYA Biosciences Revenue
In the year 2024, IDEAYA Biosciences had annual revenue of $7.00M, down -70.07%. IDEAYA Biosciences had revenue of $7.00M in the quarter ending December 31, 2024, with 78.48% growth.
Revenue (ttm)
$7.00M
Revenue Growth
-70.07%
P/S Ratio
219.60
Revenue / Employee
$53,435
Employees
131
Market Cap
1.65B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IDYA News
- 7 days ago - Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
- 10 days ago - IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PRNewsWire
- 14 days ago - IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PRNewsWire
- 21 days ago - Why Ideaya Biosciences Is Down Despite Many Positives - Seeking Alpha
- 23 days ago - IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - PRNewsWire
- 24 days ago - IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PRNewsWire
- 27 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PRNewsWire